Introduction
The pricing of life-saving orphan drugs presents a profound ethical dilemma at the intersection of the Right to Health and Life under Article 21 and the protection of Intellectual Property Rights (IPRs) that incentivize pharmaceutical innovation. This conflict balances the immediate clinical survival of vulnerable rare-disease patients against the long-term commercial sustainability required to discover new therapies.
(a) Key Ethical, Constitutional, and Bioethical Issues
The situation involves complex trade-offs between legal duties, human rights, and market realities across multiple stakeholders:
- Constitutional Tensions: The state faces a dual obligation to improve public health and secure equitable access under Article 47 and Article 39(b) of the Constitution, contrasted against its duty to protect intellectual property and foster commercial enterprise.
- Bioethical Principles: There is a direct clash between Beneficence (preserving patient lives), Justice (fair and non-discriminatory access to medicine), and Non-maleficence (avoiding policy actions that suppress future biomedical research, which indirectly harms future generations).
- Fiduciary Responsibility vs. Social Welfare: Multinational pharmaceutical corporations face an obligation to deliver returns on high-risk, capital-intensive research and development (R&D), running counter to the public interest in preventing catastrophic Out-of-Pocket Expenditure (OOPE) for families.
(b) Price-Cap Model and Secondary Market Distortions
While an administrative price ceiling directly tackles immediate affordability, it often generates severe secondary distortions in the pharmaceutical ecosystem:
- Secondary Distortions: Artificially suppressed pricing disincentivizes innovators, prompting R&D capital flight, non-launch or complete withdrawal of orphan drugs from the national market, and the emergence of unregulated grey and black markets.
- The 'No Cap' Model: While maximizing corporate incentives for discovery, an unregulated market creates severe inequity, rendering essential medical care inaccessible to economically marginalized populations.
- Compulsory Licensing (CL) Model: Under Sections 84 and 92 of the Patents Act, 1970, compulsory licensing offers a balanced alternative by permitting domestic generic manufacturing under conditions of public health crisis or lack of affordability, while guaranteeing statutory royalties to patent holders to avert complete market exit.
- Tiered and Managed Access Pricing: Voluntary price-discrimination arrangements allow multinational firms to supply drugs to lower-income economies at subsidized rates while preserving standard pricing in affluent markets.
(c) Long-Term Measures
A sustainable framework requires statutory backing, enhanced social safety nets, and innovative financing models:
- Strategic Utilization of TRIPS Flexibilities: Invoke Section 84 (non-availability at affordable prices) and Section 92 (national health emergency or extreme urgency) of the Indian Patents Act, 1970, in full alignment with the 2001 WTO Doha Declaration on TRIPS and Public Health.
- Strengthening the National Policy for Rare Diseases (NPRD) 2021: Enhance financial ceilings beyond the existing ₹50 lakh grant for chronic Group 3 disorders (e.g., Spinal Muscular Atrophy) to secure continuous treatment, alongside the prompt operationalization of the National Fund for Rare Diseases (NFRD).
- Pooled Public Procurement: Utilize centralized procurement mechanisms through agencies like the central government or public sector health consortia to aggregate demand and negotiate substantial bulk discounts directly with original drug manufacturers.
- Digital Crowdfunding and Corporate Social Responsibility (CSR): Scale the National Rare Disease Information Portal to mobilize philanthropic contributions and earmark corporate CSR spending specifically for orphan drug therapy pools.
Conclusion
Addressing the challenge of orphan drug access requires a compassionate state to move beyond blunt price control toward a collaborative, risk-sharing ecosystem. Aligning public health financing with strategic legal flexibilities ensures that innovation is sustained while guaranteeing that no patient is denied life-saving treatment due to financial distress.